Ranitidine

Generic Name: Ranitidine

Brand Names: Good Sense Acid Reducer, Wal-zan, Zantac

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₂₂N_₄O_₃S

CAS Number: 66357-35-5

Unique Ingredient Identifier: 884KT10YB7

Background: Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as cimetidine and famotidine. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion. Ranitidine is often referred to as Zantac, and is available...

Indication: This drug is used alone or with concomitant antacids for the following conditions: short-term treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid levels. It also used in the short term treatment of active benign gastr...

Associated Conditions: Acid Aspiration Syndrome, Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastric hypersecretion, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Osteoarthritis (OA), Peptic Ulcer Disease, Rheumatoid Arthritis, Stress Ulcers, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Benign gastric ulcer healing, Benign gastric ulcers, Duodenal ulcer healing, Post-operative peptic ulcer, Recurrent hemorrhage from bleeding ulcers

Associated Therapies: -

Clinical Trials

Gastric pH in Critically Ill Patients

Phase 4

Completed

Conditions: Critically Ill Patients
Indication for Stress Ulcer Prophylaxis

Interventions: Drug: esomeprazole
Drug: ranitidine

First Posted Date: 2008-01-11

Last Posted Date: 2008-01-11

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 75

Registration Number: NCT00590928

Locations: 🇦🇹
Medical University of Vienna, Department of Medicine III, ICU, Vienna, Austria

Extending Acute Stroke Trials to the Aerial Inter-hospital Transfer Setting

Not Applicable

Completed

Conditions: Stroke

Interventions: Drug: Placebo
Drug: Ranitidine
Other: Advanced notification
Other: No advanced notification

First Posted Date: 2008-01-03

Last Posted Date: 2013-01-16

Lead Sponsor: University of Iowa

Target Recruit Count: 100

Registration Number: NCT00585351

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States

Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome

Phase 2

Terminated

Conditions: JOB's Syndrome
Hyper-IgE Recurrent Infection Syndrome
Immune Deficiency

Interventions: Drug: Ranitidine
Drug: Placebo

First Posted Date: 2007-09-11

Last Posted Date: 2013-02-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT00527878

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer

Phase 3

Completed

Conditions: Gastric Ulcer

First Posted Date: 2006-11-22

Last Posted Date: 2010-07-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 397

Registration Number: NCT00401752

Locations: 🇭🇰
Research Site, Hong Kong, Hong Kong

Comparison of a "Step-Up" Versus a "Step-Down" Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study)

Not Applicable

Completed

Conditions: Dyspepsia
Gastrointestinal Diseases

Interventions: Drug: algeldrate/magnesium oxide
Drug: ranitidine
Drug: pantoprazole

First Posted Date: 2005-11-02

Last Posted Date: 2007-08-29

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 664

Registration Number: NCT00247715

Locations: 🇳🇱
Maastricht University, Maastricht, Limburg, Netherlands
🇳🇱
Radboud University Nijmegen Medical Center, Nijmegen, Gelderland, Netherlands
🇳🇱
UMC Utrecht, Utrecht, Netherlands